

AssayMax™ Human Factor VII ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μl of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 30 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key

Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
ß								
4								
æ								
2								
1								
	A	B	C	D	Е	Ŀ	Ð	т

AssayMax[™] Human Factor VII (Factor 7) ELISA Kit

Catalog No. EF1007-8 Sample insert for reference use only WHO Standard Calibrated Positive and Low Controls Included

Introduction

Factor VII (FVII) is a vitamin K-dependent plasma glycoprotein that is synthesized in the liver and circulates in blood as a single-chain inactive zymogen with a molecular mass of 50 kDa (1). Upon tissue damage and vascular injury, the cell surface receptor and cofactor tissue factor binds and allosterically activates factor VII to its active form, factor VIIa. The tissue factor/factor VIIa complex catalyzes the conversion of both factor IX to factor IXa and factor X to factor Xa to initiate coagulation via the extrinsic pathway (2-3). Very low levels of factor VII are associated with severe coagulation disorders (4). Elevated plasma levels of factor VII coagulant activity constitute an independent risk factor for fatal outcomes of coronary heart disease in middle-aged men (5).

Principle of the Assay

The AssayMax[™] Human Factor VII ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of factor VII and factor VIIa in human **plasma and serum samples**. This assay employs a quantitative **sandwich enzyme immunoassay** technique that measures total human factor VII in approximately 4 hours. A monoclonal antibody specific for human factor VII has been pre-coated onto a 96-well microplate with removable strips. Factor VII in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human factor VII, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for **Research Use Only** and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.

- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Factor VII Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a monoclonal antibody against human factor VII.
- **Sealing Tapes:** Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Factor VII Standard: Human factor VII in a buffered protein base, calibrated against WHO 4th International Standard (440 ng, lyophilized).
- **Biotinylated Human Factor VII Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against human factor VII (120 μl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 µl).
- **Chromogen Substrate (1x):** A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).
- **Positive Control:** 1 vial, lyophilized. See insert CEF10071.
- Low Control: 1 vial, lyophilized. See insert CEF10072.

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

Microplate reader capable of measuring absorbance at 450 nm

- Pipettes (1-20 µl, 20-200 µl, 200-1000 µl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- **Plasma:** Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 10-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 10-fold sample dilution is suggested into MIX Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)				
	100x		10000x		
A)	4 μl sample : 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl.	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.		
	1000x		100000x		
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution		
	Assuming the needed volume is less than or equal to 240 μl.		Assuming the needed volume is less than or equal to 240 μl.		

Refer to Dilution Guidelines for further instruction.

Reagent Preparation

• Freshly dilute all reagents and bring all reagents to room temperature before use.

- MIX Diluent Concentrate (10x): Dilute the MIX Diluent Concentrate 10fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Factor VII Standard: Reconstitute the Human Factor VII Standard (440 ng, 880 mIU) with 2.2 ml of MIX Diluent to generate a 200 ng/ml (400 mIU/ml) standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (200 ng/ml) 2-fold with equal volume of MIX Diluent to produce 100, 50, 25, 12.5, 6.25, and 3.125 ng/ml solutions. MIX Diluent serves as the zero standard (0 ng/ml). Aliquot remaining stock solution to limit repeated freeze-thaw cycles. This solution should be stored at -20°C and used within 5 days.

Standard Point	Dilution	[FVII] (ng/ml)	[FVII] (mIU/ml)
P1	1 part Standard (200 ng/ml)	200	400
P2	1 part P1 + 1 part MIX Diluent	100	200
Р3	1 part P2 + 1 part MIX Diluent	50	100
P4	1 part P3 + 1 part MIX Diluent	25	50
P5	1 part P4 + 1 part MIX Diluent	12.5	25
P6	1 part P5 + 1 part MIX Diluent	6.25	12.5
P7	1 part P6 + 1 part MIX Diluent	3.125	6.25
P8	MIX Diluent	0.0	0.0

- Biotinylated Human Factor VII Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with MIX Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with MIX Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 μl of Human Factor VII Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 µl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 µl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Factor VII Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 μl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 μl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 30 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm **immediately**. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


• The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD	
P1	200	1.818	1.870	
Γ⊥	200	1.922	1.870	
P2	100	1.381	1.408	
12	100	1.435	1.400	
Р3	50	0.952	0.922	
13	50	0.892	0.022	
P4	25	0.591	0.613	
		0.635	01010	
P5	12.5	0.399 0.407	0.407	
		0.415		
P6	6.25	0.277	0.284	
-		0.291		
P7	3.125	0.222	0.226	
		0.230		
P8	0.0	0.163	0.165	
		0.167		
Sample: Poo		0.914	0.933	
Sodium Citrate	e Plasma (10x)	0.952	0.000	
Sample: Poo	oled Normal	0.997	1.019	
Serum	(10x)	1.041	1.019	

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human Factor VII Standard Curve



Reference Value

- Normal human factor VII plasma and serum levels range from 200 700 ng/ml.
- Plasma and serum samples from healthy adults were tested (n=40). On average, human factor VII level was 529 ng/ml.

Sample	n	Average Value (ng/ml)
Pooled Normal Plasma	10	495
Normal Plasma	20	522
Pooled Normal Serum	10	570

Performance Characteristics

- Kit standard has been calibrated against WHO International Standard.
- This assay recognizes FVII and FVIIa.
- The minimum detectable dose of human factor VII as calculated by 2SD from the mean of a zero standard was established to be 2.3 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Prec	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	5.5%	5.0%	5.7%	9.1%	8.2%	11.2%
Average CV (%)		5.4%			9.5%	

Spiking Recovery

• Recovery was determined by spiking two plasma samples with different factor VII concentrations.

Sample	Unspiked Sample (ng/ml)	Spiking Value (ng/ml)	Expected	Observed	Recovery (%)
	36.5	40.0	76.5	74.2	97%
1		20.0	56.5	52.6	93%
		10.0	46.5	46.4	100%
	18.0	40.0	58.0	55.0	95%
2		20.0	38.0	37.8	99%
		10.0	28.0	26.3	94%
Average Recovery (%)					96%

Linearity

• Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)				
Sample Dilution	Plasma	Serum		
5x	94%	102%		
10x	102%	100%		
20x	105%	98%		

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Equine	None
Monkey	<10%
Mouse	None
Rat	None
Swine	<80%
Rabbit	<5%

• No significant cross-reactivity observed with factor I (fibrinogen), factor II (prothrombin), factor III (tissue factor), factor V, factor IX, factor X, factor XI, factor XIII.

Troubleshooting

Issue	Causes	Course of Action
	Use of improper components	 Check the expiration date listed before use. Do not interchange components from different lots.
-	Improper wash step	 Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.
cisior	Splashing of reagents while loading wells	 Pipette properly in a controlled and careful manner.
Low Precision	Inconsistent volumes loaded into wells	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
	Improperly sealed microplate	 Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.

	1	
_	Microplate was left	Each step of the procedure should be performed
na	unattended between	uninterrupted.
jg	steps	
h S	Omission of step	 Consult the provided procedure for complete list of steps.
ligl	Steps performed in	 Consult the provided procedure for the correct order.
Т.	incorrect order	
ito	Insufficient amount of	 Check pipette calibration.
ly Low ol Intensity	reagents added to wells	 Check pipette for proper performance.
Unexpectedly Low or High Signal Intensity	Wash step was skipped	Consult the provided procedure for all wash steps.
tec	Improper wash buffer	 Check that the correct wash buffer is being used.
ect	Improper reagent	 Consult reagent preparation section for the correct
đx	preparation	dilutions of all reagents.
ne	Insufficient or	 Consult the provided procedure for correct incubation
5	prolonged incubation	time.
	periods	
		 Sandwich ELISA: If samples generate OD values higher
		than the highest standard point (P1), dilute samples
		further and repeat the assay.
E	Non-optimal sample	Competitive ELISA: If samples generate OD values lower
e/	dilution	than the highest standard point (P1), dilute samples
un 1		further and repeat the assay.
Deficient Standard Curve Fit		 User should determine the optimal dilution factor for samples.
dar	Contamination of	A new tip must be used for each addition of different
ane	reagents	samples or reagents during the assay procedure.
Sti	Contents of wells	 Verify that the sealing film is firmly in place before placing
ut u	evaporate	the assay in the incubator or at room temperature.
cie		 Pipette properly in a controlled and careful manner.
ŝfic	Improper pipetting	 Check pipette calibration.
ŏ		 Check pipette for proper performance.
	Insufficient mixing of	 Thoroughly agitate the lyophilized components after
	reagent dilutions	reconstitution.
	reasent anations	 Thoroughly mix dilutions.

References

- (1) Davie EW et al. (1979) Adv Enzyme. 48:277.
- (2) Bajaj SP et al. (1981) J Biol Chem. 256:253.
- (3) Kisiel W et al. (1975) Biochemistry. 14:4928.
- (4) Arbini AA et al. (1997) Blood. 89:176.
- (5) Junker R et al. (1997) Arterioscler Thromb Vasc Biol. 17:1539.

Version 8.7R-8